CWA's Experience

Capital West Advisors has developed biotechnology and pharmaceutical business plans for over 20 businesses including medical devices, generic pharmaceuticals, branded pharmaceuticals, genetic diagnostics, and genetic therapeutics. Capital West Advisors has 2 Managing Directors that are significantly experienced in this industry: Seth Schwartz and Reginald Nugent. Seth and Reginald have both been with Capital West Advisors for over 5 years and one or both have been involved with the financial, growth, and strategic planning for the majority of these clients. Prior to CWA, Seth worked for the Kriegsman Group, an investment bank that specifically focused on biotechnology, pharmaceuticals, and medical devices, where he developed many business plans and helped raise capital for several clients. Prior to CWA, Reginald consulted several biotechnology (and healthcare) companies and served as the CEO of a Surgical Center. Also, CWA has an Associate that is particularly experienced with biotechnology and has developed many biotech (and healthcare) business plans with Capital West Advisors.

Unique Elements of a Biotech & Pharmaceutical Business Plan

A biotechnology or pharmaceutical business plan should closely detail the development plan of the product(s) and the several stages of FDA clinical trials that each product has already passed and/or still needs to conduct and pass. The product (or technology) section should provide a strong technical description of the product, compound, or technology being developed and should often contain a “Competing Technologies” section, which technically describes similar and competing technologies. The market section should closely focus on the specific market for that category of drug, device, or compound and include statistics regarding the various diseases that the business will treat. The financial plan should closely detail the projected costs of research, development, equipment, and salaries that the business will incur to bring the product to market and beyond. A biotech or pharmaceutical business plan is typically approximately 45 to 60 pages in length. The financial plan can be 7 years (if it takes several years to get the product FDA approved). A biotech or pharmaceutical business plan will often contain an Appendix with data from clinical trials and/or intellectual property pertaining to the product. Biotechnology and pharmaceutical business plans typically range from $3500 to $6000 to develop a full business plan.